NeoGenomics, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 484.33M | 509.73M | 591.64M | 660.57M | 727.33M | 10.1% | |
| Cost of Revenue | (297.27M) | (321.83M) | (347.04M) | (370.47M) | (444.79M) | 20.1% | |
Gross Profit | 187.06M | 187.90M | 244.60M | 290.10M | 282.54M | -2.6% | |
| Operating Expenses | |||||||
| Research & Development | (21.87M) | (30.33M) | (27.31M) | (31.16M) | (37.08M) | 19.0% | |
| Selling, General & Administrative | (283.94M) | (277.91M) | (279.96M) | (310.49M) | (365.34M) | 17.7% | |
| General & Administrative | (221.35M) | (210.59M) | (209.12M) | (225.87M) | (273.34M) | 21.0% | |
| Selling & Marketing | (62.59M) | (67.32M) | (70.84M) | (84.63M) | (92.01M) | 8.7% | |
| Depreciation & Amortization | (53.35M) | (69.43M) | (72.58M) | (72.55M) | (67.82M) | -6.5% | |
Operating Income (EBIT) | -118.75M | -157.62M | -107.74M | -92.11M | -66.08M | -28.3% | |
| Non-Operating Items | |||||||
| Interest Income | 3.14M | 6.08M | 16.90M | 18.43M | 9.07M | -50.8% | |
| Interest Expense | (8.22M) | (7.58M) | (6.91M) | (6.62M) | (3.75M) | -43.3% | |
| Other Income/Expenses (Net) | 103.68M | -1.72M | 10.64M | 11.43M | -44.19M | -486.6% | |
Income Before Tax | -15.07M | -159.34M | -97.10M | -80.67M | -110.27M | 36.7% | |
| Income Tax Expense | (6.73M) | (15.09M) | (9.13M) | (1.95M) | (2.24M) | 15.1% | |
Net Income | -8.35M | -144.25M | -87.97M | -78.73M | -108.03M | 37.2% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-0 | $-6 | $-4 | $-3 | $-4 | 35.5% | |
| Weighted Avg Shares Outstanding | 23.99M | 24.84M | 25.10M | 25.33M | 25.62M | 1.1% | |
| Weighted Avg Shares Outstanding (Diluted) | 23.99M | 24.84M | 25.10M | 25.33M | 25.62M | 1.1% | |
EBITDA | 46.50M | -82.33M | -17.61M | -1.51M | -38.69M | 2460.6% |
Explore NEO
NEO in the Healthcare
Small Cap